Skip to content

Serotonin research published in 2025

Page 4 of 8: studies 61 to 80 of 151, newest first. Back to the serotonin overview

Studies

327. 5-HT2B RECEPTORS MODULATE THE ANTIDEPRESSANT-LIKE RESPONSE OF THE PSYCHEDELIC LSD IN RAT BUT NOT IN MICE

The International Journal of Neuropsychopharmacology August 1, 2025 Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.

Abstract Background Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), present a great promise for treating affective disorders. While the hallucinogenic activities of LSD are commonly attributed to stimulation of 5-HT2A receptors, their role in LSD’s antidepressant response is still in debate. Interestingly, LSD...

Ayahuasca-Induced Serotonin Syndrome: Risks, Mechanisms, and Clinical Considerations

Pharmaceutical Science August 1, 2025 Melissa Ortega

Ayahuasca is a traditional Amazonian brew composed primarily of Banisteriopsis caapi and Psychotria viridis, drawing increasing interest for its psychedelic effects and potential therapeutic applications. Its pharmacological action is based on the synergistic combination of β-carbolines (harmine, tetrahydroharmine, and harmaline), which act as reversible inhibitors of monoamine oxidase A...

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS

The International Journal of Neuropsychopharmacology August 1, 2025 Giovanni Martinotti, Clara Cavallotto, Giacomo D’andrea et al.

Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with several studies showing remission rates up to 70% in patients with treatment-resistant depression (TRD) treated with protocols involving a single or double dose administration [1,2]. Psilocybin is a psychedelic compound belonging to the tryptamine class,...

363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR

The International Journal of Neuropsychopharmacology August 1, 2025 B. D. Richardson, Marco Pileggi, Thomas Prudhomme et al.

Abstract Background Psychedelics hold potential as therapeutics in psychological disorders. Even if they primarily act on 5-HT2A receptors, their mechanisms and effects on the brain are not well understood. Simply activating 5-HT2A receptors does not induce psychedelic effects. For example, psilocybin and lisuride both bind to 5-HT2A receptors, but only psilocybin induces hallucinogenic...

The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.

Psychopharmacology August 1, 2025 Leah M Salinsky, Christina R Merritt, Erik J. Garcia et al. 8 citations

Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liability of cocaine is reliant upon inhibition of dopamine (DA) reuptake and consequent increase in DA efflux in meso-corticolimbic circuitry that controls reward and motivation. Cocaine also increases serotonin (5-HT) efflux which is integral in cocaine...

DOI: 10.1007/s00213-025-06765-3 (opens in new tab) Full text (opens in new tab) Serotonin −-2,5-dimethoxy-4-iodoamphetamine 5-ht2ar Behavioral economics +3

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology July 28, 2025 Omar Qureshi, Jamie Cowley, Ashley Pegg et al. 5 citations

Psychedelic drugs that activate 5-HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti-inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune responses, including inhibiting...

DOI: 10.1111/bph.70138 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor 5‐ht2a receptor Immune system Neuroinflammation +4

Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2

International Journal of Molecular Sciences July 26, 2025 Lena M. Rudy, Michał M. Godlewski 2 citations

Sleep paralysis (SP), an REM parasomnia, can be characterized as one of the symptoms of narcolepsy. The SP phenomenon involves regaining meta-consciousness by the dreamer during REM, when the physiological atonia of skeletal muscles is accompanied by visual and auditory hallucinations that are perceived as vivid and distressing nightmares. Sensory impressions include personification of an...

Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective.

Acta Neuropsychiatrica July 25, 2025 Guillaume Thuery, Christopher Sheridan, Patricia Iusan et al. 4 citations

By synthesising findings from both clinical and preclinical research, this review aims to provide an understanding of the interplay between 5-HT2A receptor psychedelics and the immune system and considers how their immunomodulatory effects associate with neuronal and behavioural changes. A PubMed literature search covering the past 30 years was conducted using keywords such as "5-HT2A...

A reciprocal interplay between 5-HT2A and mGlu5 receptors underlies neuroplasticity

bioRxiv Preprint Server July 23, 2025 Tomas Del Olmo, Mathilde Decourcelle, Martial Séveno et al. preprint

The serotonin (5-HT)2A receptor is the primary target of numerous psychoactive drugs including serotonergic psychedelics, and mediates psychedelics-induced neuroplasticity, but the signaling mechanisms involved remain poorly characterized. Using quantitative phosphoproteomics, we show that the administration of the hallucinogenic 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) to...

LSD's rapid antidepressant effects are modulated by 5-HT2B receptors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 16, 2025 Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al. 12 citations

Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a great promise for treating affective disorders. Interestingly, LSD displays strong functional activity on 5-HT2B receptors and a modulatory role of the latter receptors in anxious and depressive-like behaviors has been reported. Using behavioral and in...

Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease.

Alzheimer's Research & Therapy July 15, 2025 Briana K Chen, Holly C Hunsberger, Alicia Whye et al.

Alzheimer's disease (AD) is the leading cause of dementia. There are limited approved medications that delay cognitive decline or lessen neuropsychiatric symptoms. Numerous clinical trials for AD using a single drug administration have failed to meet therapeutic endpoints, which is most likely due to the complexity of AD. A multimodal therapeutic intervention is more likely to improve symptoms...

DOI: 10.1186/s13195-025-01804-9 (opens in new tab) Full text (opens in new tab) Ketamine Adjunctive treatment Neuroinflammation Prucalopride +9

5-HT2A receptors shape whole-brain monoaminergic coherence in male mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 13, 2025 Jasmine Jade Butler, Margherita Virgili, Giuseppe Di Giovanni et al. 5 citations

The mechanism of action of serotonergic psychedelics is increasingly explored worldwide due to their clinical benefits in various psychiatric conditions. Beyond the stimulation of serotonin 2 A (5-HT2A) receptors, psychedelics may desynchronize activity between brain regions, however the involvement of corresponding neurotransmission systems has been largely overlooked. Given that monoaminergic...

DOI: 10.1016/j.pnpbp.2025.111437 (opens in new tab) Full text (opens in new tab) Correlations Exploratory behavior Mdl-100,907 Neurochemistry complex neurochemistry +6

A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction

Journal of Psychopharmacology July 11, 2025 Diana Glenn, Seung Hee Choi, Rick S. Zimmerman 1 citation

Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction. Methods: A systematic...

Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice

Pharmaceuticals July 6, 2025 Pauline Braekow, Joachim Neumann, Uwe Kirchhefer et al.

Background/Objectives: Hallucinogenic substances such as psilocybin, psilocin, ergometrine, ergotamine, and lysergic acid diethylamide (LSD) have been demonstrated to enhance the force of contraction (FOC), in part due to the phosphorylation of phospholamban in human atrial preparations via 5-HT4 serotonin receptors and/or H2 histamine receptors. However, whether psilocybin or psilocin acts at...

Psychedelic 5-HT2A agonist increases spontaneous and evoked 5-Hz oscillations in visual and retrosplenial cortex.

bioRxiv : the preprint server for biology July 6, 2025 Callum M. White, Zohre Azimi, Robert Staadt et al. 1 citation preprint

Visual perception appears largely stable in time. However, psychophysical studies have revealed that theta waves (4-8 Hz) can modulate perception and have been linked to various cognitive states and functions. Neither the contribution of theta waves to cortical activity nor their impact during aberrant brain states have been resolved at high spatiotemporal scales. Here, using cortex-wide...

DOI: 10.1101/2025.07.05.663288 (opens in new tab) Full text (opens in new tab) Brain research Neurobiology Cognitive neuroscience Visual perception +15

A Dopamine-Serotonin Theory of Consciousness

arXiv Preprint Archive July 3, 2025 Diogo Sousa preprint

This work presents a comprehensive theory of consciousness grounded in mathematical formalism and supported by clinical data analysis. The framework developed herein demonstrates that consciousness exists as a continuous, non-monotonic function across a high-dimensional neurochemical space, with dopamine serving as the primary intensity regulator and serotonin (5-HT2A) as the complexity...

Full text (opens in new tab) Q-bio.nc Q-bio.ot

Serotonin 2C receptors are also important in head-twitch responses in male mice.

Psychopharmacology July 1, 2025 Raly James Perez Custodio, Darlene Mae Ortiz, Hyun Jun Lee et al. 8 citations

Serotonergic psychedelics exert their effects via their high affinity for serotonin (5-HT) receptors, particularly through activating 5-HT2A receptors (5-HT2AR), employing the frontal cortex-dependent head-twitch response (HTR). Although universally believed to be so, studies have not yet fully ascertained whether 5-HT2AR activation is the sole initiator of these psychedelic effects. This is...

Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.

Cureus July 1, 2025 Akshita Suleria, Sakshi Verma, Khanij Arya et al.

Lysergic acid diethylamide (LSD) is an ergot-derived psychedelic agent that produces perceptual and psychic effects of heightened sensations by acting on the dopaminergic, adrenergic, and serotonergic pathways in the brain and periphery, with 5-hydroxytryptamine 2A (5-HT2A) as the primary target molecule. Its action on these receptors in the central nervous system is comparatively well studied...

What fMRI studies say about the nature of the psychedelic effect: a scoping review

Frontiers in Neuroscience July 1, 2025 Michal Beneš, Tomáš Páleníček, Jiřı́ Horáček 4 citations

Research on psychedelic drugs, such as psilocybin, LSD or DMT, is a burgeoning field, with an increasing number of studies showing their promise in treatment of mental disorders as well as examining their mechanism of action. Determining their effect on the brain is crucial from clinical standpoint, but also offers highly promising avenues of advancement in basic neuroscience—functional...

DOI: 10.3389/fnins.2025.1606798 (opens in new tab) Psilocybin Serotonergic Cognitive psychology Modality human–computer interaction +1

Exploring serotonergic psychedelics as a treatment for personality disorders.

Neuropharmacology July 1, 2025 Brennan M. Carrithers, Daniel E. Roberts, Brandon M Weiss et al. 4 citations

Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy...

DOI: 10.1016/j.neuropharm.2025.110413 (opens in new tab) Full text (opens in new tab) Psychedelic drugs Character disorders Magic mushroom therapy Personality disorders +6